Lumito AB signs a Letter of Intent with Katana Labs GmbH
Lumito has signed a "Letter of Intent” with Katana Labs in Germany to offer a cloud and AI-based image analysis solution to Lumito's future customers with "scanning-service agreements". For potential customers to easily evaluate Lumito's product SCIZYS, a "scanning service" is offered. This enables customers to evaluate the benefits of SCIZYS without first investing in […]
Lumito AB publishes Quarterly Report 2, 2024
First half of the year1 January – 30 June 2024 Net sales amounted to KSEK 17 (0). Result after taxes amounted to KSEK -15,244 (-14,668). Basic and diluted earnings per share amounted to SEK -0,06 (-0,07). Cash flow from operating activities after change in working capital amounted to KSEK -16,247 (-13,734). Cash and cash equivalents […]
Lumito has CE-marked its first product SCIZYS
Lumito has CE-marked its first product, SCIZYS. This is an important milestone for Lumito and means that sales for the histopathological research market can begin. SCIZYS S1 now fulfils all the relevant provisions of the EC Machinery Directive 2006/42/EC. The internal work required to be able to CE mark the product after receiving the final […]
The last day of trading with the warrants of series TO5 in Lumito AB is today, June 4, 2024
Today, June 4, 2024, is the last day of trading with the warrants of series TO5 in Lumito AB (publ) (“Lumito” or the “Company”). The exercise period for the warrants runs up to and including June 10, 2024. Each warrant of series TO5 gives the owner the right to subscribe for one (1) new share […]
The subscription price for exercise of warrants of series TO5 in Lumito AB is set to SEK 0.75 and the subscription period commences today May 27
Lumito AB (publ) ("Lumito" or the "Company") issued warrants of series TO5 in connection to an issue and loan financing during the fourth quarter of 2023. Each warrant gives the right to subscribe for one (1) new share in the Company. The subscription price for the warrants has been set to 70 percent of the […]
Lumito AB publishes Quarterly Report 1, 2024
Financial overview of the first quarter January 1 to March 31, 2024 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -7 113 (-7 245). Earnings per share before and after dilution amounted to SEK -0,03 (-0,04). Cash flow from operating activities after changes in working capital amounted to TSEK -7 180 […]
Lumito attends the Digital Pathology & AI Congress in London
On December 7–8, Lumito will exhibit with a booth at the annual Digital Pathology & AI Congress in London. The presence is part of the company's branding work within the company's primary target group ahead of the upcoming launch of SCIZYS. – It is important for us to build trust around our brand and product. […]
Lumito has started an internal pilot study for multiplexing
Lumito has started a pilot study where the aim is to investigate the possibilities of multiplexing by adding another nanoparticle label to the company's unique UCNP-based technology. There is a pronounced need from the market regarding requests for multiplexing to facilitate further and streamline the work within tissue analysis. Lumito already offers multiplexing with today's […]
Lumito AB publishes Quarterly Report 3, 2023
Financial overview of the third quarterJuly 1 to September 30, 3023 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -5 358 (-6 815). Earnings per share before and after dilution amounted to SEK -0,03 (-0,04). Cash flow from operating activities after changes in working capital amounted to TSEK -6 101 […]
Watch Mattias Lundin’s presentation at the BioStock Life Science Summit on October 25
On October 25, Mattias Lundin, Lumito's CEO, presented the company and the strategy going forward at the BioStock Life Science Summit in Lund. The presentation can be viewed afterwards here: Lumitos Presentation at the BioStock Life Science Summit October 25, 2023 For further information, please contact: Mattias Lundin, CEO LumitoE-mail: ml@lumito.sePh: +46 76 868 45 09 […]
